{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T13:30:43Z","timestamp":1784035843912,"version":"3.55.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1053\/j.seminoncol.2016.02.018","type":"journal-article","created":{"date-parts":[[2016,2,24]],"date-time":"2016-02-24T13:01:28Z","timestamp":1456318888000},"page":"419-425","source":"Crossref","is-referenced-by-count":23,"title":["Cutaneous manifestations of nontargeted and targeted chemotherapies"],"prefix":"10.1053","volume":"43","author":[{"given":"Veronica J.","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren L.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer N.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2016.02.018_bib1","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jaad.2008.05.018","article-title":"Toxic erythema of chemotherapy: a useful clinical term","volume":"59","author":"Bolognia","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1053\/j.seminoncol.2016.02.018_bib2","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.jaad.2014.03.019","article-title":"Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management","volume":"71","author":"Miller","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1053\/j.seminoncol.2016.02.018_bib3","first-page":"2307","article-title":"The pathogenetic mechanism of anthracycline-induced palmar-plantar erythrodysesthesia","volume":"29","author":"Martschick","year":"2009","journal-title":"Anticancer Res"},{"key":"10.1053\/j.seminoncol.2016.02.018_bib4","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/cncr.23333","article-title":"Matched case-control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel-induced onycholysis and cutaneous toxicity of the foot","volume":"112","author":"Scotte","year":"2008","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2016.02.018_bib5","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1517\/14728214.2014.946403","article-title":"Emerging therapies for the prevention and treatment of oral mucositis","volume":"19","author":"Yuan","year":"2014","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1053\/j.seminoncol.2016.02.018_bib6","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1002\/1097-0142(19930901)72:5<1612::AID-CNCR2820720520>3.0.CO;2-Q","article-title":"A longitudinal study of oral ulcerative mucositis in bone marrow transplant recipients","volume":"72","author":"Woo","year":"1993","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2016.02.018_bib7","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1159\/000366246","article-title":"Adverse event management of oral mucositis in patients with breast cancer","volume":"9","author":"Seiler","year":"2014","journal-title":"Breast Care (Basel)"},{"key":"10.1053\/j.seminoncol.2016.02.018_bib8","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1159\/000348524","article-title":"Management of cytotoxic extravasation\u2014ASORS expert opinion for diagnosis, prevention and treatment","volume":"36","author":"de Wit","year":"2013","journal-title":"Onkologie"},{"key":"10.1053\/j.seminoncol.2016.02.018_bib9","first-page":"113","article-title":"Vinca alkaloid skin toxicity: antidote and drug disposition studies in the mouse","volume":"74","author":"Dorr","year":"1985","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.seminoncol.2016.02.018_bib10","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/bjd.13743","article-title":"The risk of nail changes with taxane chemotherapy: a systematic review of the literature and meta-analysis","volume":"173","author":"Capriotti","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1053\/j.seminoncol.2016.02.018_bib11","first-page":"334","article-title":"The irreplaceable image: Nails changes in onco-hematologic patients","volume":"86","author":"Vassallo","year":"2001","journal-title":"Haematologica"},{"key":"10.1053\/j.seminoncol.2016.02.018_bib12","first-page":"327","article-title":"Targeting epidermal growth factor receptor signaling: early results and future trends in oncology","volume":"35","author":"Lage","year":"2003","journal-title":"Ann Med"},{"key":"10.1053\/j.seminoncol.2016.02.018_bib13","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11523-009-0114-0","article-title":"Skin toxicities associated with epidermal growth factor receptor inhibitors","volume":"4","author":"Li","year":"2009","journal-title":"Target Oncol"},{"key":"10.1053\/j.seminoncol.2016.02.018_bib14","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000112795","article-title":"Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results","volume":"72","author":"Boone","year":"2007","journal-title":"Oncology"},{"key":"10.1053\/j.seminoncol.2016.02.018_bib15","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/j.1365-2133.2006.07452.x","article-title":"The PRIDE (Papulopustules and\/or paronychia, Regulatory abnormalities of hair growth, Itching, and Dryness due to Epidermal growth factor receptor inhibitors) syndrome","volume":"155","author":"Lacouture","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1053\/j.seminoncol.2016.02.018_bib16","first-page":"6","article-title":"The growing importance of skin toxicity in EGFR inhibitor therapy","volume":"23:194","author":"Lacouture","year":"2009","journal-title":"Oncology (Williston Park)"},{"key":"10.1053\/j.seminoncol.2016.02.018_bib17","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1200\/JCO.2004.11.057","article-title":"Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer","volume":"22","author":"Perez-Soler","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2016.02.018_bib18","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1200\/JCO.2005.00.6916","article-title":"Cutaneous adverse effects with HER1\/EGFR-targeted agents: is there a silver lining?","volume":"23","author":"Perez-Soler","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2016.02.018_bib19","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/cncr.23621","article-title":"Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB)","volume":"113","author":"Jatoi","year":"2008","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2016.02.018_bib20","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1200\/JCO.2008.21.7828","article-title":"Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer","volume":"28","author":"Lacouture","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2016.02.018_bib21","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1200\/JCO.2007.12.6987","article-title":"Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption","volume":"25","author":"Scope","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2016.02.018_bib22","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00520-011-1197-6","article-title":"Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities","volume":"19","author":"Lacouture","year":"2011","journal-title":"Support Care Cancer"},{"key":"10.1053\/j.seminoncol.2016.02.018_bib23","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jaad.2014.07.032","article-title":"Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane","volume":"72","author":"Macdonald","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1053\/j.seminoncol.2016.02.018_bib24","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s00520-012-1404-0","article-title":"Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors","volume":"20","author":"Peuvrel","year":"2012","journal-title":"Support Care Cancer"},{"key":"10.1053\/j.seminoncol.2016.02.018_bib25","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jaad.2005.10.010","article-title":"Dermatologic side effects associated with the epidermal growth factor receptor inhibitors","volume":"55","author":"Agero","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1053\/j.seminoncol.2016.02.018_bib26","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.critrevonc.2013.11.007","article-title":"Cutaneous manifestations of anti-angiogenic therapy in oncology: review with focus on VEGF inhibitors","volume":"90","author":"Ishak","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1053\/j.seminoncol.2016.02.018_bib27","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1200\/JCO.2005.03.6723","article-title":"Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma","volume":"24","author":"Ratain","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2016.02.018_bib28","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1634\/theoncologist.2008-0131","article-title":"Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib","volume":"13","author":"Lacouture","year":"2008","journal-title":"Oncologist"},{"key":"10.1053\/j.seminoncol.2016.02.018_bib29","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1529-8019.2011.01435.x","article-title":"Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib","volume":"24","author":"McLellan","year":"2011","journal-title":"Dermatol Ther"},{"key":"10.1053\/j.seminoncol.2016.02.018_bib30","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1200\/JCO.2009.23.4823","article-title":"Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib","volume":"27","author":"Arnault","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2016.02.018_bib31","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00520-008-0409-1","article-title":"Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib","volume":"16","author":"Rosenbaum","year":"2008","journal-title":"Support Care Cancer"},{"key":"10.1053\/j.seminoncol.2016.02.018_bib32","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1001\/jamadermatol.2014.2734","article-title":"Cutaneous adverse effects associated with the tyrosine-kinase inhibitor cabozantinib","volume":"151","author":"Zuo","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1053\/j.seminoncol.2016.02.018_bib33","doi-asserted-by":"crossref","first-page":"e312","DOI":"10.1200\/JCO.2009.26.4432","article-title":"Profound hair and skin hypopigmentation in an African American woman treated with the multi-targeted tyrosine kinase inhibitor pazopanib","volume":"28","author":"Sideras","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2016.02.018_bib34","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1096\/fasebj.9.9.7601337","article-title":"The MAPK signaling cascade","volume":"9","author":"Seger","year":"1995","journal-title":"FASEB J"},{"key":"10.1053\/j.seminoncol.2016.02.018_bib35","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1634\/theoncologist.2012-0333","article-title":"Analysis of dermatologic events in vemurafenib-treated patients with melanoma","volume":"18","author":"Lacouture","year":"2013","journal-title":"Oncologist"},{"key":"10.1053\/j.seminoncol.2016.02.018_bib36","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1468-3083.2012.04546.x","article-title":"Cutaneous side effects of inhibitors of the RAS\/RAF\/MEK\/ERK signalling pathway and their management","volume":"27","author":"Manousaridis","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1053\/j.seminoncol.2016.02.018_bib37","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s11912-013-0308-6","article-title":"Dermatological adverse events from BRAF inhibitors: a growing problem","volume":"15","author":"Belum","year":"2013","journal-title":"Curr Oncol Rep"},{"key":"10.1053\/j.seminoncol.2016.02.018_bib38","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2016.02.018_bib39","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2016.02.018_bib40","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1365-2133.2012.11155.x","article-title":"Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma","volume":"167","author":"Anforth","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1053\/j.seminoncol.2016.02.018_bib41","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jaad.2012.04.008","article-title":"Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study","volume":"67","author":"Chu","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1053\/j.seminoncol.2016.02.018_bib42","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/exd.12249","article-title":"No human virus sequences detected by next-generation sequencing in benign verrucous skin tumors occurring in BRAF-inhibitor-treated patients","volume":"22","author":"Ganzenmueller","year":"2013","journal-title":"Exp Dermatol"},{"key":"10.1053\/j.seminoncol.2016.02.018_bib43","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2016.02.018_bib44","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S1470-2045(14)70051-8","article-title":"Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study","volume":"15","author":"Larkin","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminoncol.2016.02.018_bib45","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2016.02.018_bib46","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S1470-2045(12)70431-X","article-title":"Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial","volume":"13","author":"Long","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminoncol.2016.02.018_bib47","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/jid.2012.268","article-title":"Topical 5-fluorouracil elicits regressions of BRAF inhibitor-induced cutaneous squamous cell carcinoma","volume":"133","author":"Viros","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1053\/j.seminoncol.2016.02.018_bib48","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1111\/bjd.12519","article-title":"Systemic retinoids for the chemoprevention of cutaneous squamous cell carcinoma and verrucal keratosis in a cohort of patients on BRAF inhibitors","volume":"169","author":"Anforth","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1053\/j.seminoncol.2016.02.018_bib49","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1200\/JCO.2011.41.1660","article-title":"Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition","volume":"30","author":"Zimmer","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2016.02.018_bib50","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2016.02.018_bib51","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/ijd.12205","article-title":"Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions","volume":"53","author":"Curry","year":"2014","journal-title":"Int J Dermatol"},{"key":"10.1053\/j.seminoncol.2016.02.018_bib52","doi-asserted-by":"crossref","first-page":"e67583","DOI":"10.1371\/journal.pone.0067583","article-title":"Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF\/MEK tool combination reduced skin lesions","volume":"8","author":"King","year":"2013","journal-title":"PLoS One"},{"key":"10.1053\/j.seminoncol.2016.02.018_bib53","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1016\/j.jaad.2012.12.963","article-title":"The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis","volume":"69","author":"Minkis","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1053\/j.seminoncol.2016.02.018_bib54","doi-asserted-by":"crossref","first-page":"40","DOI":"10.12788\/j.sder.0061","article-title":"Dermatologic adverse events to chemotherapeutic agents, Part 2: BRAF inhibitors, MEK inhibitors, and ipilimumab","volume":"33","author":"Choi","year":"2014","journal-title":"Semin Cutan Med Surg"},{"key":"10.1053\/j.seminoncol.2016.02.018_bib55","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2016.02.018_bib56","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jaad.2014.02.035","article-title":"Ipilimumab in patients with cancer and the management of dermatologic adverse events","volume":"71","author":"Lacouture","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1053\/j.seminoncol.2016.02.018_bib57","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1158\/1078-0432.CCR-14-2468","article-title":"Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma","volume":"21","author":"Gibney","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2016.02.018_bib58","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial","volume":"384","author":"Robert","year":"2014","journal-title":"Lancet"},{"key":"10.1053\/j.seminoncol.2016.02.018_bib59","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1158\/2326-6066.CIR-14-0134","article-title":"Lichenoid dermatitis in three patients with metastatic melanoma treated with anti-PD-1 therapy","volume":"3","author":"Joseph","year":"2015","journal-title":"Cancer Immunol Res"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775416000439?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775416000439?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T19:14:26Z","timestamp":1567624466000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775416000439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":59,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S0093775416000439"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2016.02.018","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]}}}